Peritumoral ductular reaction: a poor postoperative prognostic factor for hepatocellular carcinoma

BMC Cancer

Table 3 Univariate and multivariate analyses of prognostic factors

Variable	Overall survival			Recurrence-free survival
	Univariate	Multivariate		Univariate	Multivariate
	p	HR (95% CI)	p	p	HR (95% CI)	p
Age, year (≤50 vs >50)	0.719		N.A.	0.881		N.A.
Gender (female vs male)	0.013		N.A.	0.003		N.A
ALT, U/L (≤40 vs >40)	0.264		N.A.	0.800		N.A.
γ-GT, U/L (≤55 vs >55)	0.030		N.A.	0.581		N.A.
ALP, U/L (≤121 vs >121)	0.007		N.A	0.077		N.A
Serum albumin, g/L (<35 vs ≥35)	0.632		N.A	0.712		N.A
AFP, ng/ml (≤20 vs >20)	0.095		N.A.	0.169		N.A.
HBsAg (negative vs positive)	0.207		N.A.	0.449		N.A.
Tumor size, cm (≤5 vs >5)	6.0E-05	2.950 (1.694-5.137)	1.3E-04	0.003	1.804 (1.057-3.080)	0.031
Tumor number (single vs multiple)	0.006		N.A.	3.3E-05		N.A.
Tumor capsule (yes vs none)	0.016		N.A.	0.015		N.A.
Microscopical intrahepatic metastasis (no vs yes)	0.165		N.A.	0.021		N.A.
Microscopic vascular invasion (no vs yes)	0.354		N.A.	0.017		N.A.
Portal vein invasion (no vs yes)	0.004		N.A.	0.348		N.A.
BCLC stage (A vs B/C)	3.3E-08	2.738 (1.602-4.679)	2.3E-04	2.2E-07		N.A.
TNM stage (I vs II /III)	1.8E-07		N.A.	3.4E-08	3.597 (2.046-6.324)	8.8E-06
Necroinflammatory grade (<9 vs ≥9)	0.001		N.A.	0.003	1.837 (1.087-3.105)	0.023
Fibrotic stage (≤4 vs >4)	0.014		N.A.	0.103		N.A.
DR (<2 vs ≥2)	2.6E-05	4.294 (2.255-8.177)	9.3E-06	4.8E-04	2.380 (1.250-4.534)	0.008
Liver ischemic time, min (≤25 vs >25)	0.760		N.A.	0.683		N.A.
Blood loss, ml (<800 vs ≥800)	0.007		N.A.	0.063		N.A.
Blood transfusion (yes vs no)	0.089		N.A.	0.071		N.A.

The median was used as cut-off of necroinflammatory grade, fibrotic stage and DR respectively. Variables with p <0.05 in univariate analysis were adopted for multivariate analysis. Tumor size and DR were included, other covariates including tumor number, tumor capsule and portal vein invasion were then excluded.

ISSN: 1471-2407